Objective: This study assesses the quality and completeness of systematic reviews (SRs) included by the National Comprehensive Cancer Network (NCCN) cancer screening clinical practice guidelines (CPGs).
Methods: We evaluated SRs according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and AMSTAR-2 (A Measurement Tool to Assess systematic Reviews).
Results: Seven NCCN CPGs were included with 109 SRs. The mean PRISMA percent completeness of included SRs was 71 % (range 0.1–1.0). The mean AMSTAR-2 percent completeness was 56 % (range 0.05−0.99). Of the 70 SRs assessed via AMSTAR-2, 42 (60 %) received a “critically low” rating, 11 (15.7 %) received “low” ratings, and 17 (24.3 %) received “moderate”. None of the SRs received a “high” rating.
Conclusion: Lack of adherence to AMSTAR-2 and PRISMA reporting standards among the SRs included is prevalent. We suggest improved reporting of SR inclusion criteria and evaluation to bolster the reporting quality of SRs underpinning CPG recommendations.
- Cancer screening
- Clinical practice guidelines
- Systematic reviews